The South San Francisco, CA-based biopharmaceutical company leverages its oligonucleotide and small molecule platforms to develop drugs for use in combo regimens for viral and liver diseases. Lead program, comprised of four candidates, is aimed at a functional cure for chronic hepatitis B virus (HBV) infection. Another program, with one candidate at present, is focused on NASH, currently preclinical.
2020 Financials (6 mo.): Operating Expenses: $42.0M (+99%); Net Loss: ($40.8M) (-104%); Cash Burn: ($38.0M) (-108%).